Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer | BMC Cancer | Full Text

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer | BMC Cancer | Full Text

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

There is no established second-line treatment after failure of gemcitabine plus nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this study was to evaluate the efficacy and t...

Authors:Masashi Sawada, Akiyoshi Kasuga, Takafumi Mie, Takaaki Furukawa, Takanobu Taniguchi, Koshiro Fukuda, Yuto Yamada, Tsuyoshi Takeda, Ryo Kanata, Masato Matsuyama, Takashi Sasaki, Masato Ozaka and Naoki Sasahira

Citation:BMC Cancer 2020 20:449

Content type:Research article

Published on: 20 May 2020

• ViewFull Text
 
• ViewPDF